SCHEMBL2081672

SCHEMBL2081672

O=Cc1ncccc1NC(=O)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.60
NPC1 O15118 5/20 0.54
RAB9A P51151 5/20 0.54
POLB P06746 3/20 0.50
MDM4 O15151 1/20 0.50
TP53 P04637 1/20 0.50
HDAC3 O15379 1/20 0.50
MAPK1 P28482 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.50
HPGD P15428 1/20 0.50
KMT2A Q03164 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
PABPC1 P11940 1/20 0.47
ALDH1A1 P00352 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12676693 0.83 RAB9A (0.43) KDRNPC1RAB9APOLBKMT2A
SCHEMBL30117873 0.81 RAB9A (0.79) KDRNPC1RAB9APOLBKMT2A
SCHEMBL3096372 0.81 RAB9A (0.79) KDRNPC1RAB9APOLBKMT2A
SCHEMBL13319566 0.80 MEN1 (0.65) NPC1RAB9APOLBTP53KMT2A
SCHEMBL25313098 0.79 MEN1 (0.55) POLBMAPK1HPGDKMT2ACYP1A2
SCHEMBL29809493 0.79 MEN1 (0.55) POLBMAPK1HPGDKMT2ACYP1A2
SCHEMBL27990883 0.79 KDR (0.65) KDRNPC1RAB9APOLBMDM4
SCHEMBL27578898 0.79 KDR (0.65) KDRNPC1RAB9APOLBMDM4
SCHEMBL2771907 0.78 HDAC1 (0.67) KDRNPC1RAB9APOLBMDM4
SCHEMBL11339458 0.78 KDR (0.63) KDRNPC1RAB9APOLBMDM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1613613-B1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS GENZYME CORP (US) 2021-06-02 EP disclosed
US-7863293-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2011-01-04 US disclosed
EP-1613613-A4 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC (CA) 2009-03-25 EP disclosed
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED CORPORATION (CA) 2008-10-16 US disclosed
US-7291631-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2007-11-06 US disclosed
EP-1613613-A2 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2006-01-11 EP disclosed
WO-2004091518-A2 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2004-10-28 WO disclosed
US-20040209921-A1 CXCR4 chemokine receptor binding comounds ANORMED CORPORATION (CA) 2004-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209921-A1 CXCR4 chemokine receptor binding comounds CXCR4, CXCR1, CXCR3 KDR 475/4885NPC1 1612/4885RAB9A 899/4885
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS CXCR4, CXCR1, CXCR3 KDR 259/4885NPC1 1188/4885RAB9A 983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.